Idm Pharma (IDMI) 10-Q 2006 Q2 Quarterly report

Exhibit 32.1

CERTIFICATION¹

     Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Jean-Loup Romet-Lemonne, M.D., the Chief Executive Officer of IDM Pharma, Inc. (the “Company”), and Hervé Duchesne de Lamotte, the Acting Principal Financial and Accounting Officer of the Company, each hereby certifies that, to the best of his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2006, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and results of operations of the Company for the period covered by the Periodic Report. Dated: August 14, 2006

/s/ Jean-Loup Romet-Lemonne	/s/ Hervé Duchesne de Lamotte
Jean-Loup Romet-Lemonne, M.D.	Hervé Duchesne de Lamotte
Chief Executive Officer	Acting Principal Financial and Accounting Officer

¹ This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of IDM Pharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.